For the quarter ending 2025-09-30, ACRS had -$146K decrease in cash & cash equivalents over the period. -$10,955K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -14,614 | -30,514 |
| Depreciation and amortization | 110 | 242 |
| Stock-based compensation expense | 2,860 | 6,598 |
| Revaluation of contingent consideration | 100 | 1,800 |
| Accounts receivable | - | -124 |
| Accounts receivable, prepaid expenses and other assets | -6,810 | - |
| Accounts payable | 377 | 4,107 |
| Prepaid expenses and other assets | - | -7,031 |
| Accrued expenses and other liabilities | 1,295 | -10,643 |
| Deferred income | -715 | -1,795 |
| Net cash used in operating activities | -10,932 | -23,050 |
| Purchases of property and equipment, net | 23 | 64 |
| Purchases of marketable securities | 5,198 | 29,926 |
| Proceeds from sales and maturities of marketable securities | 19,051 | 54,989 |
| Payment of deferred transaction consideration for in-licensed assets | 0 | 833 |
| Net cash provided by investing activities | 13,830 | 24,166 |
| Payment of deferred transaction consideration for in-licensed assets | 3,044 | - |
| Payments of employee withholding taxes related to restricted stock unit award vesting | 0 | 284 |
| Net cash used in financing activities | -3,044 | -284 |
| Net increase in cash and cash equivalents | -146 | 832 |
| Cash and cash equivalents at beginning of period | 24,570 | - |
| Cash and cash equivalents at end of period | 25,256 | - |
Aclaris Therapeutics, Inc. (ACRS)
Aclaris Therapeutics, Inc. (ACRS)